These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24458149)

  • 1. The safety, pharmacokinetics, and efficacy of intraocular celecoxib.
    Kim SJ; Toma H; Shah R; Kompella UB; Vooturi SK; Sheng J
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1409-18. PubMed ID: 24458149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of eye pigmentation on transscleral drug delivery.
    Cheruvu NP; Amrite AC; Kompella UB
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):333-41. PubMed ID: 18172110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
    Amrite AC; Edelhauser HF; Kompella UB
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):320-32. PubMed ID: 18172109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
    Chen M; Li X; Liu J; Han Y; Cheng L
    J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation.
    Barañano DE; Kim SJ; Edelhauser HF; Durairaj C; Kompella UB; Handa JT
    Br J Ophthalmol; 2009 Oct; 93(10):1387-90. PubMed ID: 19628498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes.
    Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R
    Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study.
    Kim SJ; Adams NA; Toma HS; Belair ML; Thorne JE; Green WR; Jabs DA
    Retina; 2008 Apr; 28(4):595-605. PubMed ID: 18398362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits.
    Ye YF; Gao YF; Xie HT; Wang HJ
    Mol Vis; 2014; 20():629-36. PubMed ID: 24868137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and efficacy of intraocular flurbiprofen.
    Blazaki S; Tsika C; Tzatzarakis M; Naoumidi E; Tsatsakis A; Tsatsanis C; Tsilimbaris MK
    Graefes Arch Clin Exp Ophthalmol; 2017 Dec; 255(12):2375-2380. PubMed ID: 28963579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular toxicity of intravitreal clarithromycin.
    Unal M; Peyman GA; Liang C; Hegazy H; Molinari LC; Chen J; Brun S; Tarcha PJ
    Retina; 1999; 19(5):442-6. PubMed ID: 10546942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis.
    Sakurai E; Nozaki M; Okabe K; Kunou N; Kimura H; Ogura Y
    Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4845-52. PubMed ID: 14578407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental study to evaluate safety/toxicity of intravitreal natalizumab.
    Chawla R; Nath M; Moksha L; Nag TC; Velpandian T
    Indian J Ophthalmol; 2018 Oct; 66(10):1441-1445. PubMed ID: 30249830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration.
    Ayalasomayajula SP; Kompella UB
    Pharm Res; 2004 Oct; 21(10):1797-804. PubMed ID: 15553225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and prevention effect of intraocular crocetin in proliferative vitreoretinopathy.
    Wang HF; Ma JX; Shang QL; An JB; Chen HT; Wang CX
    Biomed Pharmacother; 2019 Jan; 109():1211-1220. PubMed ID: 30551371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis.
    Jaffe GJ; Yang CS; Wang XC; Cousins SW; Gallemore RP; Ashton P
    Ophthalmology; 1998 Jan; 105(1):46-56. PubMed ID: 9442778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
    Mruthyunjaya P; Khalatbari D; Yang P; Stinnett S; Tano R; Ashton P; Guo H; Nazzaro M; Jaffe GJ
    Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
    Park SJ; Choi Y; Na YM; Hong HK; Park JY; Park KH; Chung JY; Woo SJ
    Invest Ophthalmol Vis Sci; 2016 May; 57(6):2612-7. PubMed ID: 27258433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
    Amrite AC; Ayalasomayajula SP; Cheruvu NP; Kompella UB
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1149-60. PubMed ID: 16505053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.